Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPEROR phase 3 study of zorevunersen in Dravet syndrome
CTR20262328Phase 3Active
- Sponsor
- Stoke Therapeutics
- Start
- Aug 2025
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of zorevunersen in Dravet syndrome, sponsored by Stoke Therapeutics. Started Aug 2025; status: active.
02
Drugs
zorevunersen
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on CTR20262328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262328.